New cancer drug HCB301 enters first human tests for tough tumors

NCT ID NCT06487624

First seen Feb 05, 2026 · Last updated May 01, 2026 · Updated 9 times

Summary

This early-phase study tests an investigational drug called HCB301 in adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 50 participants will receive the drug through an IV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    RECRUITING

    Kaohsiung City, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Prisma Health-Upstate

    RECRUITING

    Greenville, South Carolina, 29605, United States

  • Southern Medical University Zhujiang Hospital

    RECRUITING

    Zhujiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xuzhou Central Hospital

    RECRUITING

    Xuzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yantai Yuhuangding Hospital

    RECRUITING

    Yantai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Provincial Cancer Hospital

    RECRUITING

    Hangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.